# Synergistic Combinations Shikonin usually looks stronger in combination than alone. That pattern appears across more than one cancer type and more than one partner drug. ### Tamoxifen This is the most developed combination story. Tamoxifen blocks ERα activation. Shikonin reduces ERα abundance and weakens related downstream signalling. In ER-positive breast-cancer cells, the combination shows synergistic growth inhibition and may reduce the dose of tamoxifen needed for the same effect. ### Cisplatin In bladder-cancer models, shikonin can re-sensitise cisplatin-resistant cells. The logic depends on PKM2 inhibition and necroptosis induction. This is not just added toxicity. It is pathway-based resistance reversal. ### Doxorubicin Breast-cancer work suggests shikonin can increase doxorubicin sensitivity. The likely explanation is complementary stress, with metabolic and pro-death pressure added to doxorubicin's DNA-damage effect. ### Gefitinib-related combinations In NSCLC, some shikonin derivatives have re-sensitised gefitinib-resistant cells. That is a real finding. It belongs more to the derivative story than to native shikonin alone. ### The main caution Every combination listed here is preclinical. Synergy in a dish does not guarantee safety in a patient. Interaction risk, timing, tissue exposure, and healthy-organ toxicity can change the picture completely. ### Bottom line Shikonin is not mainly interesting as a solo agent. Its strongest translational promise may sit in combination settings. That promise still needs pharmacokinetic and safety work before it becomes clinically meaningful. ### Key references Zhang L et al. (2020). Shikonin and 4-hydroxytamoxifen synergistically inhibit proliferation in ER+ breast cancer.\ Li Z et al. (2018). Shikonin synergy with cisplatin via PKM2/necroptosis in bladder cancer. *PMC.*\ Ahmad F et al. (2024). Combination findings with doxorubicin — breast cancer models. *Journal of Pharmacy and Pharmacology.*\ Yang J et al. (2019). Gefitinib sensitisation context — EGFR degradation pathway. *European Journal of Pharmacology.*\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/synergistic-combinations.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.